Dual targeting of the PI3K and MAPK pathways in breast cancer

Asia-Pacific Journal of Oncology and Hematology

Volumn 2, Issue 2, 2010, Pages

  Saini, Kamal S ^a   Piccart Gebhart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Dual inhibition; Raf MEK ERK

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; BKM 120; EVEROLIMUS; GDC 0973; GSK 1120212; GSK 2141795; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MK 2206; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SELUMETINIB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CELL SURVIVAL; DRUG TARGETING; HUMAN; MOLECULAR INTERACTION; PHASE 1 CLINICAL TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW;

EID: 79951568982     PISSN: 17596637     EISSN: 17596645     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Altekruse SF, Kosary CL, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. November 2009. http://seer.cancer.gov/csr/1975_2007/. Accessed July 15, 2010.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
3. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-2334.
4. Kaplan DR, Whitman M, Schaffhausen B, et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell. 1987;50(7): 1021-1029.
5. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627-644.
7. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005; 65(23):10992-11000.
8. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010; 107(22):10208-10213.
9. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annual Review of Biochemistry. 1998;67:481-507.
10. 85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene. 2008;27(33):4569-4579.
11. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 2002;80(2):239-256.
12. Ignatiadis M, Bedard P, Haibe-Kains B, et al. A meta-analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal-like breast cancer. San Antonio Breast Cancer Symposium (Poster 106). 2009.
13. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590-603.
14. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. International Journal of Cancer. 2009;125(10):2332-2341.
15. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K -dependent feedback loop in human cancer. The Journal of Clinical Investigation. 2008;118(9):3065-3074.
16. Loi S, Haibe-Kains B, Brown DN, et al. Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: implications for anti-HER2 therapy [abstract 522]. J Clin Oncol. 2010;28 (suppl):7s.
17. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15(14):4649-4664.
18. Chang Q, Chen E, Hedley DW. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biology & Therapy. 2009;8(20):1893-1901.
19. Vincent T, DeVita J. The most important news at ASCO 2009. Nature Reviews Clinical Oncology. 2009;6:371.
20. Sheridan C. Firms combine experimental cancer drugs to speed development. Nature Biotechnology. 2010;28(8):765-766.
21. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews. 2010;36(3):206-215.
22. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737): 235-244.